Skip to content
Loading...
All Sources
All Years

13 Jun, 2023

A-TANGO highlights at EASL Congress 2023

The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. This novel combinatorial therapy is called G-TAK. In addition, A-TANGO strives to…

12 Jun, 2023

MICROB-PREDICT highlights at EASL Congress 2023

MICROB-PREDICT aims to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to…

07 Jun, 2023

LITMUS highlights at EASL Congress 2023

Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint Undertaking, brings together clinicians and scientists from prominent academic centres across Europe with companies from…

12 Apr, 2023 -

Tribute to Prof. Peter Ferenci (1948-2023)

Dear colleagues and friends: We have to share the sad news that Peter Ferenci has passed away on 11 April 2023 just a few weeks before his 75th birthday. He recently celebrated…

Back To Top